4D Molecular Therapeutics FDMT EBIT

EBIT at other companies

Eli LillyLLY

$9.25B+36.4%

Regeneron PharmaceuticalsREGN

$1.29B+19.8%

Vertex PharmaceuticalsVRTX

$1.25B+8.3%

EyePoint, Inc.EYPT

-$97.38M-56.5%

AbbVieABBV

$6.43B+31.4%

RegenxbioRGNX

$29.26M+146%

FAQ

What is 4D Molecular Therapeutics's EBIT?

4D Molecular Therapeutics (FDMT) reported EBIT of -$73.62M in Q1 2026.

How has 4D Molecular Therapeutics's EBIT changed year-over-year?

4D Molecular Therapeutics's EBIT decreased by 37.3% year-over-year, from -$53.62M to -$73.62M.

What is the long-term trend for 4D Molecular Therapeutics's EBIT?

Over 4 years (2021 to 2025), 4D Molecular Therapeutics's EBIT has grown at a 25.0% compound annual growth rate (CAGR), from -$71.33M to -$174.26M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.